• rheumatoid arthritis
  • inflammatory bowel disease (Crohn disease; ulcerative colitis)
drug interactions
or cautions
  • hypersensitivity to adalimumab, tuberculosis, opportunistic infection, sepsis, moderate-to-severe heart failure (NYHA class III/IV)
Drug interactions
  • abatacept, belimumab, certolizumab, infliximab, natalizumab, tacrolimus
  • patients should be evaluated for latent tuberculosis infection with a tuberculin skin test prior to therapy.
  • treatment of latent tuberculosis should be initiated before use.
Adverse Effects
(common and severe)
  • headache
  • skin rash
  • upper respiatory tract infection
  • sinusitis
  • tuberculosis
  • malignancy
Instructions and dose
(initial; typical)
indication-specific dosing (rheumatoid arthritis: 40 mg every other week subcutaneously; inflammatory bowel disease: 160 mg given as four 40 mg injections on day 1 or given as two 40 mg injections per day over 2 consecutive days)
  • signs and symptoms of active infection (including tuberculosis)
  • complete blood count with differential
  • signs/symptoms/worsening of heart failure
Source of Suggestion
Commonly prescribed medication (Added on August, 2016)